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The intracellular routes of sphingolipid trafficking are related to the compartmentalized nature of sphingolipid metabolism, with synthesis
beginning in the endoplasmic reticulum, continuing in the Golgi apparatus, and degradation occurring mainly in lysosomes. Whereas bulk
sphingolipid transport between subcellular organelles occurs primarily via vesicle-mediated pathways, evidence is accumulating that sphingolipids
are found in subcellular organelles that are not connected to each other by vesicular flow, implying additional trafficking routes. After discussing
how sphingolipids are transported through the secretory pathway, I will review evidence for sphingolipid metabolism in organelles such as the
mitochondria, and then discuss how this impacts upon our current understanding of the regulation of intracellular sphingolipid transport.
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Sphingolipids (SLs) are ubiquitous components of animal
cell membranes, and over the past couple of decades have
become the focus of renewed attention by biochemists, cell
biologists and biophysicists. Part of the reason for this renewed
enthusiasm is the realization that SLs play important roles in a
variety of intra- and extra-cellular signalling pathways, and that
they also appear to be key components in membrane rafts or
microdomains. The first solid evidence for the role of SLs in
signalling was obtained in the mid-1980s (reviewed in [1–4])⁎ Tel.: +972 8 9342704; fax: +972 8 9344112.
E-mail address: tony.futerman@weizmann.ac.il.
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doi:10.1016/j.bbamem.2006.08.004and the suggestion that SLs might play roles in rafts, and hence
in the intracellular trafficking pathways that rafts might
regulate, was proposed in the late 1980s [5]. Since then, there
has been tremendous progress in SL research, reflected in the
large number of reviews recently published, and, for instance, in
this special issue of Biochim Biophys Acta, devoted to SLs in
apoptosis and disease.
In this review I will focus on the intracellular trafficking of
SLs per se in mammalian cells. I will not deal with the roles that
SLs might play in directing the traffic of other cellular
components, or in the possible roles that they play in rafts,
since these issues have been extensively reviewed elsewhere
(see for instance [6,7], and Gulbins, this issue). Rather, I will
focus on how SLs are transported from their sites of synthesis to
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unexpected transport pathways that are coming to light with
the discovery of SL metabolism in unexpected subcellular
locations. I will not discuss the pathways or modes of
internalization of SLs via endocytosis, since this issue has
been reviewed recently in detail [9], suffice to say that
significant progress has been made in delineating the relation-
ship between clathrin- and non-clathrin mediated internalization
pathways, using a combination of fluorescently labelled SLs
[10], and toxins [11] that specifically bind to glyco-SLs (GSLs).
2. SL transport in the exocytic pathway
One of the limitations in the study of SL trafficking is the
relatively restricted number of appropriate experimental tools,
at least compared to what is available for the study of protein
trafficking, for which a combination of radioactive tracers and
antibodies, as well as subcellular fractionation, electron
microscopy, and more recently, proteomics approaches [12],
can be readily used. None of these techniques are particularly
applicable to the study of SL trafficking since it is difficult or
impossible to radioactively label a subset of endogenous SLs
and follow their transport and maturation, antibodies are not
readily available (except for those raised against some GSLs
[13] and some simple SLs such as ceramide), and lipid mixing
can easily occur during subcellular fractionation or during the
preparation steps of electron microscopy. Lipidomics, which
attempts to characterize global changes in lipid metabolites in
individual cell types, has recently received a lot of press (see
http://www.lipidmaps.org); however, another level of analysis
needs to be added to the current lipidomics approaches in order
to determine the lipid composition of particular organelles [14].
These kinds of problems were the main motivation behind the
development of fluorescent lipid probes to follow the
intracellular transport of SLs in real time in living cells. Since
these fluorescent probes are by definition SL analogues, they
have been the source of some criticism, much of it based on
their altered biophysical properties compared to their natural
counterparts, but it is fair to say that their usefulness, at least in
defining the major SL intracellular transport pathways, has far
outweighed their limitations.
The modern era of the study of intracellular SL trafficking was
initiated by the pioneering work of Pagano and colleagues in the
early 1980s, who synthesized a series of short-acyl chain SL
analoguescontaininga fluorophore (7-nitrobenz-2-oxa-1,3-diazole;
NBD). Due to their short acyl chain (normally C6), these analogues
were more water-soluble than their natural counterparts, and
could be added to cells from exogenous sources (such as
liposomes or complexes with bovine serum albumin), since
they readily diffused as monomers in aqueous solutions. Initial
experiments using C6-NBD-ceramide demonstrated that this
lipid was internalized by a non-energy-dependent mechanism,
and subsequently accumulated in the Golgi apparatus [15,16]
where it was metabolized to C6-NBD-sphingomyelin (C6-
NBD-SM) and C6-NBD-glucosylceramide (C6-NBD-GlcCer)
[17]), suggesting that the Golgi apparatus was the major site of
ceramide metabolism rather than the other intracellular siteswhich had been proposed earlier. Based on this work, it was
later shown by biochemical studies, using short-acyl chain
radioactive ceramides [18], that the Golgi apparatus is indeed
the site of ceramide metabolism to SM [19,20] and GlcCer
[21,22], and taken together with the demonstration that
ceramide is synthesized in the endoplasmic reticulum (ER)
[23,24], lead to the concept that SL synthesis is compartmen-
talized between the ER and the Golgi apparatus [25]. This
being the case, ceramide would need to be transported
between the ER, its site of synthesis, and the Golgi apparatus,
its site of further metabolism. Furthermore, the use of C6-
NBD-ceramide led to the proposal of differential transport of
C6-NBD-SM and C6-NBD-GlcCer to the apical and basolat-
eral surfaces of Madin–Darby canine kidney (MDCK)
epithelial cells [26], which was the foundation of the paradigm
that the sorting of SLs in the Golgi apparatus into distinct
transport vesicles might be important in the regulation of
protein transport to different plasma membrane (PM) domains
[27].
Although this reminder of some of the early studies using
fluorescent SL analogues might not appear terribly useful nearly
20years later, it does establish a useful framework for further
discussion (Fig. 1). For instance, is the idea that the early steps
of SL synthesis occur uniquely in the ER still valid? Likewise,
does further metabolism occur mainly in the Golgi apparatus?
Has the molecular identification of most of the enzymes in the
biosynthetic pathway changed our thinking in this regard? What
are the implications of the answers to these questions to
understanding the pathways of SL trafficking, and the mode of
regulation of these pathways?
The molecular identification of most, if not all of the enzymes
that synthesize SLs, has unambiguously confirmed that ceramide
is synthesized to a large extent in the ER, with subsequent
metabolism occurring in the Golgi apparatus (reviewed in [28]).
One of the most exciting recent developments in this field has
been the identification of a protein, CERT, which mediates the
transport of ceramide from the ER to theGolgi apparatus in a non-
vesicular manner [29]. CERT is a cytoplasmic protein with a
phosphatidylinositol-4-monophosphate-binding domain and a
putative domain for catalyzing lipid transfer. This protein spe-
cifically extracts ceramide from phospholipid bilayers and shows
very little activity towards other related SLs or glycerolipids.
CERT also extracts dihydroceramide but displays a relatively
restricted fatty acid specificity, efficientlymediating the transfer of
ceramides containing C14–C20 fatty acids, but is less efficient
towards ceramide containing longer chain fatty acids [30]. CERT
is involved in the delivery of ceramide for SM synthesis, but not
for GlcCer synthesis, which depends on the supply of ceramide
via a distinct ATP- or cytosol-independent (or less dependent)
pathway [31]. A specific inhibitor of CERT, N-(3-hydroxy-1-
hydroxymethyl-3-phenylpropyl)dodecanamide (HPA-12) has
been described [30,32], and this inhibitor could presumably be
used to determine the role of CERT in SL biosynthesis in other
subcellular compartments and also in various signalling
paradigms.
The specificity of CERT towards ceramides with different
fatty acid compositions [30] raises a number of questions about
Fig. 1. A simplified overview of some open questions relating to SL trafficking. Subcellular organelles are shown in black, the metabolic events that occur in them are
in blue, the major transport pathways are shown as blue arrows, and some open questions in SL trafficking in red. Poorly defined transport pathways are shown as
dashed lines. The only pathway not discussed in detail in this review is that of SL internalization, which occurs via a combination of clathrin and non-clathrin mediated
events [9–11].
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assurance) proteins [28], CERT, and down-stream steps of SL
synthesis. For instance, does CERT select which ceramide
species to preferentially remove from the ER based on a specific
protein–protein interaction of CERT with a particular LASS
protein, or with a region of the membrane enriched in specific
ceramides, or alternatively, is there no specificity in these
interactions with CERT simply picking up the most readily
accessible ceramide species? Once CERT delivers a particular
ceramide species to the Golgi apparatus, is there a difference in
the way these ceramides are handled by the receiving Golgi
apparatus membranes, or does the specificity and opposing
topology of GlcCer and SM synthases determine how the
ceramide will be further metabolized? By way of example, the
C18-ceramides made by LASS1 (formerly known as uog1) are
preferentially channelled into neutral GSLs rather than acidic
GSLs (i.e. gangliosides) [33]. The reason for this is not known,
since C18-fatty acids are found in SL species other than neutral
GSLs, but does suggest a level of complexity with respect to
ceramide synthesis, transport and further metabolism that needs
to be unravelled. Likewise, how are the longer-chain ceramides
(i.e. C22–26) delivered to the Golgi apparatus? Are they
delivered inefficiently by CERT, or are most of them delivered
by vesicular transport, or by another ceramide transfer protein?
These longer chain ceramides are synthesized mainly by LASS2
and 3 (Pankova-Kholmyansky and Futerman, unpublished
observations). Nothing is known to date about the regulation
of the different LASS genes, but they mainly appear to be
localized to the ER; might different LASS genes be localized todifferent sub-domains of the ER, which as a result might affect
how they interact with CERT or with the vesicular transport
pathways involved in transporting ceramide from the ER to the
Golgi apparatus? As is often the case, it is relatively easy to
formulate the questions, but providing answers to these
questions will be a major and exciting challenge in the years
ahead.
While considerable progress has been made in understanding
the mode of non-vesicular transport of ceramide from the ER to
the Golgi apparatus, much less progress has been made in
understanding the dynamic relationship between this pathway
and the vesicular transport pathways that are known to deliver
both proteins and lipids from the ER to the Golgi. GlcCer
synthesis is unrelated to CERT, suggesting that the pool of
ceramide utilized by GlcCer synthase is delivered to the Golgi
by vesicular transport mechanisms (reviewed in [34]). Interest-
ingly, the active site of GlcCer synthase is on the cytosolic
surface of the Golgi apparatus [35], whereas subsequent steps of
GSL synthesis occur on the lumenal surface [28]; although this
has been known for some years, the reason remains unclear.
One possibility is that GlcCer needs to be removed rapidly from
the Golgi apparatus under certain conditions before it is
metabolized to lactosylceramide on the lumenal surface.
Consistent with this is the existence of a GlcCer transfer protein
(the glycolipid transfer protein (GLTP)), whose 3D structure
was recently resolved [36]. Although these elegant structural
studies provide some of the first detailed information about how
a lipid transfer protein interacts with and removes GSLs from
lipid bilayers, they do not provide any data about the function of
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mediated transfer of GSLs in cellular events; this is particularly
apparent in light of the relatively inefficient release of GSLs
mediated by the GLTP [37], raising the possibility that this
protein may have additional functions in vivo than just the
intermembrane transfer of glycolipids. Clearly, lipid transfer
proteins cannot provide a feasible mechanism to account for the
bulk flow of lipids between one organelle and another [38],
since lipid transfer proteins are normally stoichiometric with
respect to lipid molecules, whereas vesicles can transfer
thousands of lipid molecules per transport step [38]. This
suggests that lipid transfer proteins are more likely to modulate
a local lipid environment in lipid-mediated cellular signalling
events, such as has been suggested for the phosphatidylinositol
transfer proteins [39], rather than act as bulk lipid transporters.
However, the essential role of CERT in SM synthesis does
imply a vital role for at least CERT in bulk SM synthesis,
although the precise mechanism is not yet known.
The transport pathways of SM and complex GSLs between
Golgi cisternae are presumably similar to those used by
proteins, and transport pathways from the Golgi apparatus to
the cell surface also appear to involve mainly vesicle-mediated
pathways. Whether these lipids are sorted into distinct transport
vesicles either in the Golgi apparatus or as they leave the trans-
Golgi network (TGN) has been the subject of intense study
[6,40], but it appears axiomatic that there must be a sorting step
somewhere in the Golgi apparatus if different SLs are to be
sorted to different PM domains, such as the apical and
basolateral domains of epithelial cells, or the axonal and
dendritic domains of neurons. The rules governing these sorting
events have not been fully established, but may result from the
different biophysical properties of SLs which could lead to
phase separation in the TGN, such as has recently been
observed in the apical membrane of epithelial cells [41], which
itself could impact upon how the SLs are incorporated into
vesicles as they exit the TGN. Additional sub-compartments
might also be involved in sorting and trafficking in polarized
cells [42], as might non-conventional vesicular transport
pathways [43].
One additional useful tool for examining the relationship
between SL synthesis and transport is the use of specific
inhibitors of the biosynthetic pathway (see also Casas, this
issue), such as myriocin, an inhibitor of serine palmitoyl
transferase (SPT), fumonisin B1, an inhibitor of dihydrocer-
amide synthase, and HPA-12, a specific inhibitor of CERT.
Work in our laboratory in the mid-1990s demonstrated specific
effects of inhibiting SL synthesis on axonal and dendritic
growth in hippocampal neurons, and using a combination of
inhibitors and short-acyl chain lipids, we were able to determine
distinct roles for specific SLs and GSLs at various steps of
neuronal development [44–46]. For instance, we showed that
ongoing GlcCer synthesis was required for normal axonal
development [47] and for enhancing axonal growth rates by
growth factors [48], but we could not identify the molecular
requirement for ongoing GlcCer synthesis or transport. More
recently it was shown that the formation and/or transport of a
subset of axonally-targeted vesicles is coupled to SL synthesis[49], and direct effects of inhibiting SL synthesis on the
transport and secretion of a number of proteins have now been
shown. Prominent among these are the effects of inhibiting
GlcCer synthesis on secretion of the β-amyloid precursor
protein and amyloid β-peptide [50]. This is but one of many
examples showing that interfering with SL synthesis and/or
transport can have profound effects on protein transport and on
other cellular processes, although mechanistic information is
lacking to date about how ongoing SL synthesis is coupled to
vesicular transport and/or the delivery of specific proteins from
one compartment to the other.
Finally, it should be mentioned that SL synthesis can also
occur at the PM. However, it is normally assumed that SL
synthesis at the PM acts to remodel pre-existing SLs rather than
as de novo synthesis. For instance, a particular isoform of SM
synthase is found at the PM [51], but its role is presumably
restricted to resynthesis of SM from ceramide after the latter has
been formed by SM turnover in a signalling pathway. This
concept is supported by the occurrence of a number of enzymes
of SL degradation at the PM which have neutral pH optima, or
by the translocation of some acidic enzymes (such as acidic
sphingomyelinase [52]) from the lysosome to the PM during
signalling paradigms; however, apart from the presence of small
amounts of some GSL glycosyltranferases (and of SM synthase)
at the PM, there is little evidence for the presence of other
biosynthetic enzymes at the PM. Thus, although some
remodelling can occur at the PM, the main mechanism of
determining the SL composition of the PM involves their
intracellular synthesis and trafficking from the ER and/or Golgi
apparatus.
3. SLs in unexpected places—Implications for trafficking
So far, I have focused on the trafficking of SLs through and
along the secretory pathway. Although various open questions
remain to complete our understanding of the modes of transport
along this pathway, many of the basic rules have been
established, at least in general terms. This is, however, not the
case for other transport pathways, and in particular those which
involve subcellular organelles that are not connected to the
endomembrane system by vesicle-mediated transport. Such
organelles are the mitochondria and the nucleus, and evidence
has accumulated over the past few years that some steps of SL
metabolism may occur in these organelles. If this suggestion is
supported by further experimental evidence, it will have a major
impact on our understanding of SL trafficking and function.
The importance of determining whether SL metabolism
occurs in mitochondria, or whether SLs are localized to this
organelle, cannot be underestimated since the mitochondria is a
major site of regulation of apoptosis, and mitochondrial
ceramide has been implied in this process [53]. Indeed, both
short and long acyl-chain ceramides have been shown to form
large protein permeable channels in mitochondrial outer
membranes [54], and such channels, if formed by endogenous
ceramides, could provide a mechanism to release proapoptotic
proteins from mitochondria during the induction phase of
apoptosis [55,56]. Of considerable relevance is a recent study
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from exogenous sources to cells, can be directly targeted to
mitochondria. These positively charged ceramides increase
inner membrane permeability and trigger release of mitochon-
drial cytochrome c [57].
But what is the evidence that endogenous ceramide is actually
found in mitochondria or synthesized therein? A partially
purified ceramide synthase has been purified from a mitochon-
dria-enriched fraction [58], although as with all subcellular
fractions, careful analysis of the extent of contaminating
membranes must be performed. Since ceramide synthases
(LASS proteins) have recently been identified, it should now
be possible to directly visualize their intracellular localization.
To date there is no evidence that any LASS proteins are localized
to mitochondria [28,33,59]; however, all of these studies have
examined the localization of ectopically-expressed proteins
since antibodies are not currently available to the LASS proteins
themselves.
A number of other studies have implied that ceramide or SM
[60,61] are found in mitochondria, and there is some evidence
for the existence of GSLs in mitochondria [62–64], but inherent
difficulties in separating mitochondria from mitochondria-
associated ER membranes (MAM) emphasizes the need to
directly visualize enzymes of SL metabolism in mitochondria.
There is also evidence that complex GSLs, particularly
ganglioside GD3, can be trafficked to, and affect the properties
of mitochondria [65–68], and finally, mitochondrial sialidases
[69] and ceramidases [70] have been reported.
Having said all of this, it is essential to critically evaluate the
data that ceramides and GSLs are found in, and perhaps even
synthesized in mitochondria, before this becomes unchallenged
dogma. But assuming that this turns out to be correct, what
impact would this have on our understanding of SL trafficking?
Three broad possibilities exist. The first is that a complete
subset of enzymes responsible for SL metabolism is found in
mitochondria, meaning that SL transport to mitochondria would
not be necessary. The second is that there are essentially no
enzymes of SL metabolism associated with mitochondria,
meaning that SLs would need to be transported to mitochondria,
and moreover, be targeted to the correct intra-mitochondrial
membrane. The third possibility is a combination of the above
two, in which some metabolites would be imported into
mitochondria, whereas others would be locally synthesized, as
occurs with other pathways of mitochondrial metabolism [71].
Based on the possible localization of at least some enzymes of
SL biosynthesis in mitochondria, the latter would seem to be the
most likely possibility.
Since no pathways of vesicular transport are known to
connect mitochondria to other organelles, SL transport would
have to occur either by non-vesicular facilitated mechanisms,
using molecules such as CERT or GLTP, or by direct membrane
contact between the ER and mitochondria. A close apposition
between the ER and mitochondria has long been observed, and
such membrane contacts have been suggested to play roles in
the transport of phosphatidylserine [72] and phosphatidylcho-
line [73] between MAM and mitochondria, and for the ER-
mediated sequestration of cytosolic calcium by mitochondria[74]. Morphological evidence indicates that phosphatidylserine
transfer between the ER and mitochondria occurs at these zones
of apposition [75] although the molecular machinery respon-
sible for this transfer remains unknown [76]. If phospholipids
can be transported between the ER and mitochondria, is there
any reason that SLs and ceramide should be any different [77]?
On first consideration, the answer might appear to be ‘no’, but
the added complexities of SL metabolism, such as the
compartmentalized synthesis between the ER and the Golgi,
and the unique topologies of SL synthesis on both sides of these
membranes [28], does pose challenging questions. How would
GSLs and SM, synthesized on the lumenal leaflet of the Golgi
apparatus be transported through contact sites to mitochondria?
Might the lipid transfer proteins play a role in this? The situation
with ceramide is somewhat easier to envisage, since it is
synthesized on the cytosolic surface of the ER and could
therefore be transferred to mitochondria through contact sites
without convoluted topological acrobatics.
In addition to mitochondria, a SM cycle has also been
proposed in the nucleus, with both SM synthase and sphingo-
myelinases suggested to be present [78–80], possibly associated
with the nuclear membrane and chromatin. Chromatin SMase
activity may increase in relation to cell proliferation whereas SM
synthase activity may increase during the apoptotic process [81].
Other enzymes have also been proposed to occur in the nucleus,
such as a ceramidase [82], as have some SLs themselves [64],
and these have been suggested to play important roles in
signalling [83]. As is the case with mitochondria, compelling
evidence that enzymes of SL metabolism are found in
mitochondria awaits studies using the tools recently made
available based on the molecular identification of the enzymes,
rather than on subcellular fractionation.
To further illustrate that our thinking with respect to SL
trafficking may be undergoing a minor revolution, I would like
to discuss work from our laboratory which suggests that
complex GSLs, and GlcCer, can be transported to the ER from
the endocytic pathway, at least in lysosomal storage diseases
(LSDs). We have observed effects of GSLs on Ca2+-home-
ostasis in the ER [84], implying that sufficient amounts of SLs
accumulate in the ER during these diseases to affect events
regulated in this organelle. Since SLs are known to accumulate
in lysosomes in LSDs, how could they reach the ER [85]?
Gangliosides that associate with lipid rafts have been shown to
mediate transport of cholera and related toxins from the PM to
the ER [86], and analysis of the ganglioside composition of
highly purified ER membranes shows that they contain small
but significant levels of ganglioside GM1. Based on these data,
it was proposed that the toxins hijack a pre-existing retrograde
transport pathway from the PM to the ER, perhaps in a lipid raft
structure [86]. Sorting of raft components may occur either at
the level of the PM by different mechanisms of endocytosis [9],
or after arrival in the endosomal/lysosomal compartment. Since
the latter is the major site of GSL accumulation in the storage
diseases, it does not take too much of a stretch of the
imagination to envisage that this pathway may become
overloaded and thus shunt more GSLs to the ER than normal
in GSL storage diseases. This has been demonstrated in a study
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model of the GM1 gangliosidosis [87]. In further support of this
hypothesis are our observations that microsomes isolated from a
Gaucher mouse model [88], human Gaucher brain tissue
[89,90], and brains from Sandhoff mice [91], all contain
elevated levels of either GlcCer (in the Gaucher models) or
GM2 (in the Sandhoff and Niemann–Pick A models). Although
the same criticism as applied above to the lack of purity of
mitochondrial membranes can be applied to these microsomal
fractions, it should be stressed that a direct correlation exists, for
instance, between the extent of agonist-induced Ca2+-release
and levels of GlcCer accumulation in human Gaucher brain
microsomes [90]. Clearly, direct and quantitative analysis of
GSL levels in highly purified ER is required, but the available
data strongly suggest that under certain pathophysiological
conditions (and perhaps also under physiological conditions) a
trafficking pathway exists to transport SLs from organelles in
the endocytic pathway to the ER. Interestingly, contact sites
have also been observed between the PM and the ER [92],
which together with the observations on contact sites between
mitochondria and the ER, suggests that new trafficking
pathways with respect to SL transport await to be delineated.
4. Concluding comments
About a decade ago it was commonly assumed, at least by
this author, that there was little left to discover with respect to
pathways of intracellular SL trafficking [25]. However, recent
discoveries that SLs appear to be localized in unanticipated
locations, and in particular in organelles that are not
interconnected by vesicular transport pathways, has stimulated
new thinking on this issue. How are the ‘classical’ pathways of
trafficking, i.e. through the endomembrane system, connected
to the new pathways, both in terms of trafficking of individual
classes of SLs, and perhaps of more interest, in terms of
function? The latter question is of great relevance to this
volume, and it is to be hoped that resolving this issue will help
provide mechanistic explanations for the roles that SLs play in
apoptosis and disease.
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